Metabolic Syndrome Augments the Risk of Early Neurological Deterioration in Acute Ischemic Stroke Patients Independent of Inflammatory Mediators: A Hospital-Based Prospective Study

Table 2

Logistic regression analysis for the association of MetS and its components with END in ischemic stroke patients.

	Univariate analysis	Model 1	Model 2
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Central obesity	0.98 (0.51–1.88)	1.04 (0.52–2.10)	0.84 (0.42–1.68)
Hyperglycemia	5.83 (2.81–12.08)	6.33 (2.99–13.39)	5.259 (2.49–11.12)
Elevated blood pressure	0.79 (0.34–1.84)	0.76 (0.32–1.78)	0.86 (0.35–2.08)
Decreased HDL	0.92 (0.35–2.42)	1.04 (0.38–2.86)	0.92 (0.31–2.75)
Hypertriglyceridemia	1.69 (0.85–3.38)	1.98 (0.96–4.06)	1.83 (0.88–3.82)
MetS	2.25 (1.71–4.86)	3.08 (1.54–6.16)	2.20 (1.10–4.04)

MetS, metabolic syndrome; END, early neurological deterioration; HDL, high-density lipoprotein; OR, odds ratios; CI, confidence interval; ; ; Model 1 adjusted for age and gender; Model 2 adjusted for levels of fibrinogen and hsCRP.